

# Effect of dietary fibre and exercise on knee pain

<b>Submission date</b> 19/08/2025	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 20/08/2025	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 19/08/2025	<b>Condition category</b> Musculoskeletal Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Previous research has shown that the types of bacteria that reside in your gut as well as the chemicals that they produce have implication on inflammation and pain. Furthermore, mild to moderate exercise has also shown to reduce pain in individuals with knee osteoarthritis via specific pathways. The purpose of the study is to investigate the effect of consuming a common plant derived dietary fibre on pain by changing the composition of the bacteria that reside within the gut and the levels of specific molecules called Short chain fatty acids that they produce. In addition, we will investigate the effects of exercise on compounds called endocannabinoids (i.e. cannabis like substances produced by your own body) and the effect these substances have on improving knee pain. In the current study, you will be assigned randomly assigned into a group wherein you will be asked to take a fibre supplement and/or perform a series of routine exercises for a period of 6 weeks.

### Who can participate?

You have been invited to take part in this research because you experience pain in or around a knee on most days for more than 3 months and a doctor has told you have knee osteoarthritis, you are over the age of 18, are willing and able to give informed consent for participation in the study and have a body mass index (BMI) between 20 and 39.9 kg/m<sup>2</sup>. Unfortunately, you will be unable to take part if any of the following apply: • Have a psychosocial or gastrointestinal condition (e.g. malabsorptive conditions such as IBS/IBD, coeliac) • Are taking the following medications: immunosuppressants, anticoagulants, amiodarone and/or perhexiline • Are currently following or anticipated to commence a specialised commercially available weight loss diet and/or program • Pregnant or breast feeding • History or current psychiatric illness • History or current neurological condition (e.g. epilepsy) • If you are undergoing revision, having severe hip OA, inflammatory arteriopathies • If you are diagnosed with non-OA cause of knee pain (e.g. rheumatoid arthritis) • Neuropathy or diabetes mellitus • Having taken part in a research study in the last 3 months involving invasive procedures which included an inconvenience allowance. We aim to invite 120 participants like you to take part.

### What does the study involve?

If you take part, you'll be asked to attend two study visits (one at the beginning and one at the end of the 6-week period) at the Clinical Sciences Building, City Hospital, Nottingham. At these visits, we'll collect blood and stool samples, take some physical measurements, and ask you to complete questionnaires. You'll then be randomly assigned to one of four groups: fibre

supplement, exercise programme, both fibre and exercise, or placebo. The aim is to see how these different approaches affect knee pain and health markers.

What are the possible benefits and risks of participating?

Taking part may not directly help your knee pain, but your involvement could improve understanding of how diet and exercise affect pain in people with osteoarthritis. This may help develop better treatments in the future. The risks are small: you may feel mild discomfort when blood is taken, and fibre can sometimes cause bloating or constipation (which usually settles if you drink enough water). The exercise programme is safe and commonly used but, like any exercise, may cause some muscle soreness.

Where is the study run from?

The study is being run from the University of Nottingham, with participant visits held at the Clinical Sciences Building, City Hospital, Nottingham (UK).

When is the study starting and how long is it expected to run for?

April 2022 to February 2025

Who is funding the study?

UK Medical Research Council (MRC)

Who is the main contact?

Professor Ana M. Valdes, [ana.valdes@nottingham.ac.uk](mailto:ana.valdes@nottingham.ac.uk)

## Contact information

### Type(s)

Public, Scientific

### Contact name

Dr Afroditi Kouraki

### Contact details

University of Nottingham  
Academic Rheumatology,  
Clinical Sciences Building  
Hucknall Road  
Nottingham  
United Kingdom  
NG5 1PB  
+44 115 8231676  
[afroditi.kouraki1@nottingham.ac.uk](mailto:afroditi.kouraki1@nottingham.ac.uk)

### Type(s)

Principal investigator

### Contact name

Prof Ana Valdes

### Contact details

University of Nottingham  
Academic Rheumatology,  
Clinical Sciences Building  
Hucknall Road  
Nottingham  
United Kingdom  
NG5 1PB  
+44 115 8231676  
ana.valdes@nottingham.ac.uk

## Additional identifiers

### Clinical Trials Information System (CTIS)

Nil known

### ClinicalTrials.gov (NCT)

NCT05670314

### Protocol serial number

473-0322

## Study information

### Scientific Title

Molecular signatures of endocannabinoid induced pain relief in humans: lifestyle interventions, systemic and localised changes. llifestyle iNterventionS for PaIn ReliEf (INSPIRE)

### Acronym

INSPIRE

### Study objectives

1. To assess the magnitude of the effect of prebiotic supplementation (inulin) side by side with physiotherapy exercise versus placebo (maltodextrin) on knee pain
2. To assess the combined effects of exercise and prebiotic inulin supplementation (synergistic effect) over six weeks
3. To elucidate the molecular pathways involved in pain relief induced by exercise and gut microbiome modulation in individuals with painful knee osteoarthritis

### Ethics approval required

Ethics approval required

### Ethics approval(s)

approved 29/04/2022, University of Nottingham Faculty of Medicine and Health Sciences (Faculty Hub, Room E41, E Floor, Medical School, Queen's Medical Campus, Nottingham University Hospitals, Nottingham, NG7 2UH, United Kingdom; -; FMHS-ResearchEthics@nottingham.ac.uk), ref: 473-0322

### Study design

2x2 factorial intervention trial

## **Primary study design**

Interventional

## **Study type(s)**

Efficacy

## **Health condition(s) or problem(s) studied**

Knee Osteoarthritis (OA)

## **Interventions**

Participants identified as having knee arthritis are 1:1:1:1 randomised to web-based Physiotherapy-supported Exercise (PSE), inulin, PSE and inulin or placebo and usual care. Researchers assessing outcomes were blinded to the interventions and participants were blinded to the dietary intervention. However, blinding for the PSE intervention was not feasible since participants were informed if they were assigned to one of the PSE groups or not.

PSE intervention: the study uses a digitally delivered physiotherapy platform known as Joint Academy (JA) (<https://www.jointacademy.com/gb/en/>) as a previous RCT from our group demonstrated promising results with this platform. The JA company has granted permission for this study to be carried out using their platform. The standardised PSE intervention includes tailored intensity levels and combines concentric and eccentric exercises with open- and closed-chain movements to strengthen the legs, including the hip and knee muscles, and improve balance. The programme also includes educational sessions on OA fundamentals, treatment, symptom self-management, and healthy lifestyle benefits. Participants receive an email with a link to the online platform and log-in instructions. The PSE intervention, lasting 6 weeks, begins after log-in and a kick-off call with a personal physiotherapist with participants expected to engage daily

Prebiotic intervention: Inulin fibre (20g) in powder form (commonly found in root vegetables such chicory) is randomly allocated to eligible participants. They are instructed to mix it into breakfast cereal, smoothies, yogurt, or a drink of their choice.

Placebo Group: Participants in the control placebo group continue with their usual self-management (community setting) and receive maltodextrin (10g) daily in powder form (commonly found in corn, potatoes and rice), with similar consumption instructions as inulin.

At the first visit, both groups receive pre-measured weekly pots containing either supplement or placebo, along with scoops. Participants are instructed to take 2 scoops totalling 10g/day of maltodextrin or 3 scoops totalling to 20g/day of inulin daily for 6 weeks, depending on their assigned group.

## **Intervention Type**

Mixed

## **Primary outcome(s)**

Pain measured using the Numerical Rating Scale (NRS) at baseline (1st visit) and at 6 weeks (2nd visit)

## **Key secondary outcome(s))**

1. Functional capacity is measured using the 30-second Sit-to-Stand Test (30CST) at baseline and 6 weeks
2. Functional mobility is measured using the Timed Up and Go Test (TUG), averaged over three trials, at baseline and 6 weeks
3. Muscle strength is measured using handgrip dynamometry on the dominant hand, averaged over three trials, at baseline and 6 weeks
4. Pain sensitisation is measured using Temporal Summation (TS) via quantitative sensory testing (QST) at baseline and 6 weeks
5. Pain sensitisation is measured using Pressure Pain Detection Threshold (PPT) via quantitative sensory testing (QST) at baseline and 6 weeks
6. Inflammatory protein levels are measured using Olink cytokine assay panels for IL-6, TNF, and IFN- $\gamma$  at baseline and 6 weeks
7. Gut microbiome diversity is measured using the Shannon Diversity Index derived from shotgun metagenomic sequencing of stool samples at baseline and 6 weeks
8. Short-chain fatty acid levels are measured using mass spectrometry for butyric acid and acetic acid in serum at baseline and 6 weeks
9. Serum endocannabinoid levels are measured using mass spectrometry for Anandamide (AEA) and 2-arachidonoylglycerol (2-AG) at baseline and 6 weeks
10. Pain-related gene expression is measured using RNA sequencing of whole blood samples at baseline and 6 weeks

**Completion date**

25/02/2025

## Eligibility

**Key inclusion criteria**

1. On the day of the first visit they report having any pain in or around a knee on most days for more than 3 months with a self-reported diagnosis of OA
2. Willing and able to give informed consent for participation in the study
3. Aged >18 years
4. Body mass index (BMI) between 18.5 and 39.9 kg/m<sup>2</sup>

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

19 years

**Upper age limit**

100 years

**Sex**

All

## **Total final enrolment**

171

## **Key exclusion criteria**

1. Psychosocial or gastrointestinal disorders (e.g. malabsorptive conditions such as IBS/IBD, coeliac)
2. Taking immunosuppressants, anticoagulants, amiodarone and/or perhexiline
3. Following or anticipated to commence a specialised commercially available weight loss diet and/or programme
4. Pregnant or breastfeeding
5. History or current psychiatric illness (including clinical depression)
6. Diagnosed with a neurological condition (e.g. epilepsy)
7. Already undergone a total knee replacement
8. Severe hip OA (were on a waiting list for a total hip arthroplasty)
9. Diagnosed with inflammatory arthropathies
10. Diagnosed with non-OA cause of knee pain (e.g. rheumatoid arthritis)
11. Diagnosed with neuropathy or diabetes mellitus
12. Taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance

## **Date of first enrolment**

05/07/2022

## **Date of final enrolment**

25/02/2025

## **Locations**

### **Countries of recruitment**

United Kingdom

England

### **Study participating centre**

**Nottingham University Hospitals NHS Trust - City Campus**

Nottingham City Hospital

Hucknall Road

Nottingham

United Kingdom

NG5 1PB

## **Sponsor information**

### **Organisation**

University of Nottingham

**ROR**

<https://ror.org/01ee9ar58>

## Funder(s)

**Funder type**

Research council

**Funder Name**

Medical Research Council

**Alternative Name(s)**

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

United Kingdom

## Results and Publications

**Individual participant data (IPD) sharing plan**

The datasets generated during and/or analysed during the current study will be available upon request from Dr Afroditi Kouraki, [afroditi.kouraki1@nottingham.ac.uk](mailto:afroditi.kouraki1@nottingham.ac.uk)

**IPD sharing plan summary**

Available on request

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes